Sai Life Sciences Sustainability Report - 2023-24

13 Our facilities Our facilities have received several regulatory approvals and are subject to stringent quality standards and specifications, specified by our customers. Our facilities feature flexible set-ups, including large scale reactors for high-volume products, with some of our production areas specifically designed to accommodate modern drug development pipelines that produce relatively smaller quantities but involve more intricate chemical processes. We have four main facilities, each serving a unique purpose in drug discovery, development and manufacturing and adhering to applicable standards of safety, quality and regulatory compliance, in: • Bidar, India: This serves as our primary manufacturing facility. The manufacturing blocks in our Bidar Facility are designed as multi-purpose production trains, which allows for quick changes across multiple production processes. • Hyderabad, India: This facility houses a fully integrated R&D campus for Discovery R&D, CMC process development and clinical phase manufacturing. The R&D centre within this facility houses the pilot manufacturing facility and an analytical testing and release laboratory, which have been inspected by the USFDA. • Bollaram, India : We have an intermediate manufacturing facility in Bollaram near Hyderabad, India. • Manchester, United Kingdom: We have established and expanded a laboratory set-up in our Manchester facility, titled as ‘Centre of Excellence’, in process chemistry equipped with modern laboratories. It provides development, scale-up and technology transfer to our India-based sites. • Watertown (Greater Boston, MA), United States: Our Greater Boston Facility hosts an exploratory biology laboratory and houses advanced cellular and biochemical analysis platforms.

RkJQdWJsaXNoZXIy MTIwMDc4NQ==